Evidence supporting the use of: Docosahexaenoic Acid
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Docosahexaenoic acid (DHA) is an omega-3 fatty acid that has been investigated for its potential benefits in neurological diseases, including Multiple Sclerosis (MS). The interest in DHA usage for MS is based on its anti-inflammatory properties and its critical role in maintaining neuronal membrane integrity and function. Preclinical studies in animal models of MS (such as experimental autoimmune encephalomyelitis) have shown that DHA supplementation can reduce inflammatory markers and demyelination. Some observational studies in humans have found that higher dietary intake of omega-3 fatty acids, including DHA, may be associated with a lower risk of developing MS or reduced relapse rates; however, these findings are inconsistent and often confounded by other dietary and lifestyle factors.

Randomized controlled trials specifically assessing DHA supplementation in people with MS are limited and have yielded mixed results. Most clinical studies have evaluated mixed omega-3 supplements (DHA and EPA), and systematic reviews and meta-analyses generally conclude that there is insufficient high-quality evidence to confirm a meaningful benefit of omega-3 supplementation on MS progression, relapse rate, or disability. Current MS treatment guidelines do not recommend DHA or other omega-3s as a primary therapy for MS, though they are sometimes used as complementary approaches. In summary, there is some scientific rationale and preliminary evidence for DHA's potential benefit in MS, but robust clinical validation is lacking.

More about Docosahexaenoic Acid
More about Multiple Sclerosis

Products containing Docosahexaenoic Acid

We currently have no products on Caring Sunshine that contain this ingredient.